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Background: Large databases focused on genetic susceptibility to prostate cancer have been accumulated from
population studies of different ancestries, including Europeans and African-Americans. Arab populations, however,
have been only rarely studied.
Methods: Using Affymetrix Genome-Wide Human SNP Array 6, we conducted a genome-wide association study
(GWAS) in which 534,781 single nucleotide polymorphisms (SNPs) were genotyped in 221 Tunisians (90 prostate
cancer patients and 131 age-matched healthy controls). TaqMan® SNP Genotyping Assays on 11 prostate cancer
associated SNPs were performed in a distinct cohort of 337 individuals from Arab ancestry living in Qatar and Saudi
Arabia (155 prostate cancer patients and 182 age-matched controls). In-silico expression quantitative trait locus
(eQTL) analysis along with mRNA quantification of nearby genes was performed to identify loci potentially
cis-regulated by the identified SNPs.
Results: Three chromosomal regions, encompassing 14 SNPs, are significantly associated with prostate cancer risk
in the Tunisian population (P = 1 × 10-4 to P = 1 × 10-5). In addition to SNPs located on chromosome 17q21,
previously found associated with prostate cancer in Western populations, two novel chromosomal regions are
revealed on chromosome 9p24 and 22q13. eQTL analysis and mRNA quantification indicate that the prostate
cancer associated SNPs of chromosome 17 could enhance the expression of STAT5B gene.
Conclusion: Our findings, identifying novel GWAS prostate cancer susceptibility loci, indicate that prostate cancer
genetic risk factors could be ethnic specific.
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Prostate cancer (PCa) is the most common malignancy in
western countries and the second cause of cancer-related
death in Europe and the United States [1]. With lifestyle
changes, the incidence of the disease has been increasing
in the Arab populations [2]. From 1991–2006, prostate
cancer was ranked first among cancers in Qatari* Correspondence: loc2008@qatar-med.cornell.edu
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reproduction in any medium, provided the ormales over 65 years old [3]. In Kuwait, the incidence
of prostate cancer rose to 12.3/100,000 men/year in
2004 [4]. In 2003, prostate cancer was ranked as the
fourth most diagnosed cancer in Tunisia [5]. In Lebanon,
the age-adjusted standardized incidence was 21.5/100,000
men/year in 1998 [6]. In Arab populations, the incidence
of prostate cancer correlates with low prostate volume
and testosterone. Despite the low levels of testosterone,
the aggressive forms of prostate cancer are found
frequently in Arab patients, which indicate an increased
sensitivity of Arab men to this steroid [7].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Description of the subjects for GWAS study
Case number 90
Age (mean ± SD) 73.7 ± 8.4a













Data missing 25 (33.3)
Gleason Score
GS≥ 7 44 (48.9)
GS < 7 19 (21.1)
Data missing 27 (30.0)
a Age (mean ± SD) for controls: 59.7 ± 12.6.
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disease with several genes underlying onset and severity,
and minor susceptibility genes may play a larger role in
prostate cancer risk. Recently, genome-wide association
studies (GWAS) have identified dozens of common
variants that confer susceptibility to prostate cancer across
various ethnicities from European, Asian and African
ancestry [8,9]. However, little is known about the prostate
cancer genetic susceptibility in populations of Arab ancestry.
The genetic susceptibility to prostate cancer is variable
among different populations [10]. The difference may
highlight the impact of genetic background on disease risk
between populations. For instance, several SNPs located
in 8q24 have been implied to a different population
susceptibility to prostate cancer [11,12]. These variants,
located in c-Myc gene, reduced the risk of prostate cancer
in Caucasian but not in African Americans, thus protective
mechanisms that might reduce c-Myc expression in
Caucasians do not exist in African Americans. Identification
of the genetic variants in different populations may help
us to better understand the genetic and molecular
mechanism of prostate cancer.
With the aim to identify genetic variants associated with
prostate cancer in Arab populations, we first conducted
a GWAS with DNA samples from a Tunisian cohort.
We further extended the study to evaluate potential
associations of 11 SNPs, identified by GWAS, in a cohort
from Arab ancestry living in Qatar and Saudi Arabia.
Functional significance of the identified prostate cancer
associated SNPs was assessed by in-silico analysis and
mRNA quantification of certain adjacent genes.
Materials and methods
Ethics statement
The Institutional Review Boards of Weill Cornell Medical
College in Qatar, the Hamad Medical Corporation,
and King Khalid University Hospital approved the study
protocols. All subjects signed informed consent documents
for participation in the study.
Subjects
A total of 221 unrelated Tunisian men consisting of 90
PCa patients and 131 male age-matched controls were
selected from the same population living in the middle
coast of Tunisia. PCa patients were recruited from the
two departments of Urology of Monastir and Sousse
Hospital, Tunisia, in whom the diagnosis has been
confirmed histologically. The serum prostate-specific
antigen (PSA) values were measured in all the cases before
treatment. Clinical characteristics including Gleason grade,
TNM stage, age at diagnosis, and family history were
obtained from medical records. The pathological stage at
the time of diagnosis was classified according to TNM
system into the localized group (T1− T2N0M0) and theadvanced group (T3 −T4N0 M0 and T1 −T4N0–1 M1/
T1− T4N1M0–1). Histopathological grade was recorded as
the Gleason score and was classified into two groups: the
low-grade group (Gleason score < 7) and the high-grade
group (Gleason score⩾7). A detailed description of the
clinical-pathological characteristics of this cohort is
summarized in Table 1.
The control group consisted of 131 healthy male subjects
having no evidence of any personal or family history of
cancer. Their PSA levels were within the normal limit
(<4 ng/ml) and showed no signs of prostate hyperplasia or
PCa by digital rectal examination. Those who had other
known malignancies were also excluded.
There were 155 unrelated PCa patients and 182
age-matched controls from Arab ancestry living in Qatar
and Saudi Arabia included in the replication genotyping
study.DNA and RNA extraction
Genomic DNA was extracted from peripheral blood
samples using QIAampW DNA blood Maxi Kit according
to the manufacturer’s protocol (Qiagen, Valencia, CA).
Thirty-six RNA samples were extracted from archived
formalin-fixed paraffin-embedded non-malignant prostate
tissues using RecoverAll™ Total Nucleic Acid Isolation
Kit (Ambion, Grand Island, NY).
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Genome-wide scanning was applied with Affymetrix
Genome-Wide Human SNP Array 6.0 following the
manufacturer’s protocol. After genotype calling using
the Birdsuite [13], the total SNPs on Affymetrix arrays
were subjected to quality control. Nineteen samples
were excluded due to low call rate (<95%). SNPs were
excluded with low minor allele frequency (<5%), low call
frequency (<95%) and replication error. The final SNP
set included 534,781 SNPs for genome-wide association
analysis.
The replication study was performed with the
TaqManW SNP genotyping assays on a 7500 Real-Time
PCR System (Applied Biosystems, Grand Island, NY),
with no template as negative controls. The PCR thermal
cycling was as follows: initial denaturing at 95°C for
10 min, 40 cycles of 92°C for 15 s and 60°C for 1 min.
Genotype call success rate for cases and for controls was
94.8% and 98.2% respectively. Randomly selected 47
samples were verified genotype reproducibility with a
coincidence rate 100%.
Genotyping data analysis
To stratify and correct the population, we performed a
multidimensional scaling (MDS) analysis as implemented
in PLINK 1.07 [14] on the identity-by-state (IBS) matrix of
our samples. After removing 7 outliers by plotting the
main axes of variation against each other (Additional file 1
Figure S1), we use PLINK to analyze the genome-wide
association with 498,148 autosomal SNPs and to perform
permutation test to examine the stability of P values.
Genotype distributions between cases and controls were
evaluated by the chi-square test. Associations between
genotypes/alleles and prostate cancer risk were estimated
by computing odds ratios (ORs) and the corresponding
95% confidence intervals (CI) from unconditional logistic
regression. Homozygotes for non-risk allele were the
reference group, and then heterozygotes and homozygous
risk allele genotypes were compared with the reference
group, respectively. The linkage disequilibrium analyses
were applied with Haploview [15].
eQTL analysis
All the identified consecutive loci on chromosome 9,
17 and 22, were tested for correlation with nearby
gene expression using the eQTL database Genevar [16].
Genotype and expression data within this database are
derived from 3 cell types (fibroblast, lymphoblastoid cell
line and T cell) from 75 individuals from Geneva,
Switzerland [17] and 3 tissue types (166 adipose, 156
lymphoblastoid cell line and 160 skin) from healthy female
twins [18]. The expression probes located within 1 Mb of
the 5’ and 3’ end of the specified SNPs were analyzed.
Differences in the distribution of normalized expressionlevels between genotypes were compared using a linear
regression model. To avoid false positive associations
due to multiple tests, we set a significance threshold
of P < 1.0 × 10−3 and also assessed significance using
10,000-fold permutations (Perm).
Gene expression quantification
Using GoTaqW 2-Step RT-qPCR System, total RNA
was prepared from 36 non-malignant prostate tissues
and reverse transcribed and the mRNA of genes adjacent
to the GWAS prostate cancer SNPs were quantified.
Expression values were calculated as 2-ΔCt using GAPDH
gene as reference. Primer sequences are listed in the
Additional file 2 Table S1. The difference in gene expres-
sion between prostate tumors carrying GWAS prostate
cancer risk alleles and that without was calculated using T
test with Welch’s correction.
Results
Genome Scan analysis of DNA from 90 Tunisian patients
with prostate cancer and 131 age-matched control
subjects revealed association with 5,749 SNPs (P < 0.01)
(Additional file 1 Figure S2 and Additional file 3 Table S2).
The genotype distributions of all these SNPs were in
Hardy-Weinberg equilibrium (P > 0.05, the related data
of 14 SNPs on chromosome 9, 17 and 22 are presented
in Additional file 4 Table S3). Three consecutive regions
were identified on chromosome 9, 17 and 22 encompassing
14 SNPs, which were found highly associated with prostate
cancer (P = 1 × 10-4 to P = 1 × 10-5) (Table 2). Considering
our modest sample size, we performed a permutation
test of our GWAS dataset and these 14 SNPs still
showed significant association (Additional file 5 Table S4).
The LD structures of the SNPs (with P < 0.01) located in
these 3 consecutive regions are shown in Figure 1.
To investigate whether the identified SNPs associated
with prostate cancer in other Arab populations, we
replicated the genotyping of 11 SNP in 337 subjects
from Arab ancestry living in Qatar and Saudi Arabia
(155 PCa patients and 182 age-matched control subjects).
None of these SNPs was found to be associated with
prostate cancer risk in this distinct Arab population
(Additional file 6 Table S5).
To address the functional significance of the 3 clusters
of SNPs, we investigated the potential correlation between
these SNPs and the expression of the adjacent genes. This
includes: SMARCA2 (SWI/SNF related, matrix associated,
actin dependent regulator of chromatin, subfamily a,
member 2) on chromosome 9, STAT5A (signal transducer
and activator of transcription 5A) and STAT3 (signal
transducer and activator of transcription 3) on chromosome
17 and FAM227A (family with sequence similarity 227,
member A) and SUN2 (Sad1 and UNC84 domain
containing 2) on chromosome 22. In-silico analysis using
Table 2 Fourteen SNPs identified by GWAS associated with prostate cancer risk in Tunisians
dbSNP ID Chr Gene Allelea Risk allele
frequency
HetOR(95%CI) Pb HomOR(95%CI) P Risk allele OR(95%CI) P
Case Control
Previous reported
rs1053005 17 STAT3 T/C 0.45 0.26 2.94(1.30-4.41) 4 × 10-3 4.22(1.84-9.69) 4 × 10-4 2.30(1.54-3.45) 4 × 10-5
rs8074524 17 STAT3 C/T 0.45 0.25 2.43(1.32-4.47) 4 × 10-3 5.05(2.14-12.0) 1 × 10-4 2.46(1.64-3.70) 1 × 10-5
rs3809758 17 STAT3 C/T 0.45 0.26 2.25(1.23-4.14) 8 × 10-3 4.41(1.90-10.2) 3 × 10-4 2.31(1.54-3.47) 4 × 10-5
Newly reported
rs7045455 9 SMARCA2 T/C 0.94 0.80 3.80(0.20-71.9) 0.2 12.5(0.70-222.6) 0.02 3.98(1.97-8.05) 4 × 10-5
rs12686439 9 SMARCA2 G/A 0.92 0.77 4.39(0.64-81.6) 0.16 13.2(0.74-234.5) 0.02 3.32(1.80-6.15) 7 × 10-5
rs10810919 9 SMARCA2 T/C 0.95 0.82 2.09(0.10-41.8) 0.35 9.14(0.50-167.8) 0.04 5.03(2.22-11.4) 2 × 10-5
rs10963533 9 SMARCA2 T/C 0.95 0.81 2.46(0.13-48.3) 0.31 9.30(0.51-170.9) 0.04 4.19(2.01-8.75) 5 × 10-5
rs10963540 9 SMARCA2 G/A 0.95 0.81 2.66(0.14-51.9) 0.28 11.0(0.61-198.6) 0.03 4.81(2.23-10.4) 2 × 10-5
rs12601982 17 STAT5A A/G 0.35 0.17 2.27(1.25-4.14) 7 × 10-3 6.43(2.15-19.3) 3 × 10-3 2.61(1.67-4.07) 2 × 10-5
rs8078731 17 STAT3 A/T 0.32 0.16 2.06(1.10-3.84) 0.02 5.67(1.85-17.4) 1 × 10-3 2.47(1.55-3.93) 1 × 10-4
rs5750627 22 LOC646851 C/T 0.71 0.50 1.76(0.77-4.01) 0.17 4.50(1.98-10.3) 2 × 10-4 2.40(1.60-3.60) 2 × 10-5
rs6001173 22 LOC646851 C/T 0.70 0.50 1.84(0.81-4.18) 0.14 4.30(1.89-9.78) 3 × 10-4 2.32(1.54-3.49) 4 × 10-5
rs138702 22 SUN2 T/A 0.75 0.55 3.14(1.12-8.86) 0.02 6.59(2.33-18.4) 1 × 10-4 2.44(1.60-3.71) 3 × 10-5
rs138712 22 SUN2 A/G 0.74 0.54 2.54(0.96-6.72) 0.05 5.92(2.25-15.6) 1 × 10-4 2.47(1.63-3.76) 2 × 10-5
Note: Chr, chromosome; OR, Odds ratio; CI, confidence interval; HetOR, odds ratio in heterozygote; HomOR, odds ratio in homozygote for risk allele (relative to
homozygote for non-risk allele).
a Reference allele/risk allele.
b Bold font indicates that P value reaches the adjusted significant level (i.e., 0.05/14).
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prostate cancer-identified SNPs and the expression of the
above described adjacent genes. We next expanded our
search to the 2 Mb region flanking these SNPs. The
cluster of SNPs on chromosome 17 are associated with
the expression of STAT5B gene, which encodes a signal
transducer and activator of transcription 5B, and the
risk alleles were consistently associated with increased
expression of STAT5B (Additional file 1 Figure S3A).
On chromosome 22, rs5750627 and rs6001173 SNPs are
associated with the expression of APOBEC3H (apolipopro-
tein B mRNA editing enzyme, catalytic polypeptide-like
3H), CBX6 (chromobox homolog 6), DDX17 (DEAD
box helicase 17), PLA2G6 (phospholipase A2, group
VI), KDELR3 (Lys-Asp-Glu-Leu endoplasmic reticulum
protein retention receptor 3) and CBY1 (chibby homolog 1,
Drosophila), whereas rs138702 SNP is found to be associ-
ated with APOBEC3H (Additional file 1 Figure S3B),
JOSD1 (Josephin domain containing 1), KDELR3 and
CBY1. rs138712 is associated with the expression of
APOBEC3H, CBX6, PLA2G6 and SUN2 (Additional file 1
Figure S3C). No correlation was found between GWAS
prostate cancer SNPs located on chromosome 9 and the
expression of nearby genes in the 2 Mb range.
To confirm the results obtained by in-silico analysis, we
assessed the mRNA levels of the above-described genes in
36 non-malignant prostate tissues of patients. Samplescarrying more than three risk alleles of chromosome 17
SNPs (rs12601982, rs1053005, rs8074524, rs3809758 and
rs8078731) showed significantly higher expression of
STAT5B (Figure 2A, 0.282 ± 0.083 N = 22 vs. 0.049 ±
0.016 N = 14, P = 0.011). We also examined the mRNA
levels of 4 genes located on chromosome 22: APOBEC3H,
CBY1, DDX17 and JOSD1. We observed higher levels
of APOBEC3H mRNA in prostate samples carrying
risk alleles of the GWAS prostate cancer SNPs (Figure 2B)
but the difference did not reach statistical significance
(0.043 ± 0.020 N = 18 vs. 0.006 ± 0.001 N = 14, P = 0.080.
No APOBEC3H amplification in the other 4 samples). For
the remaining chromosome 22 genes, no correlation was
found between GWAS prostate cancer SNPs and their
mRNA levels.
Discussion
With the fulfillment of the GWAS in the search of
alleles that predispose Tunisians for the prostate cancer,
we identified 3 genomic regions containing 14 SNPs, 11
of which were newly reported risky loci associated with
prostate cancer (Table 2). The region 17q21 containing
STAT3 was reported associated with prostate cancer in
the Caucasian population [19]. rs1053005 and rs3809758
(r2 = 0.93), located in 17q21, were independently associated
with more aggressive PCa [20]. Similarly, rs8074524 in
perfect LD with rs3809758 (r2 = 1.00 in the Caucasian
Figure 1 LD map of the SNPs and association results for the loci on the consecutive region of chromosome (A)9, (B)17 and (C)22.
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aggressive prostate cancer [20]. In the Tunisian population,
LD among these 3 SNPs is close to perfect (all r2 > 0.95,
Figure 1). rs12601982 residing in the intron of the STAT5A
gene is located in the same LD block as the reported
loci (r2 = 0.98), suggesting that this region may be a
promising common prostate cancer marker in different
ethnic populations.Figure 2 The correlation between risk alleles and nearby gene expres
nonrisk alleles carriers. The individuals who carry at least 3 risk alleles out o
group. The rest are enrolled in nonrisk alleles carriers group. (B) APOBEC3H
carriers. The individuals who carry 4 risk alleles of all those 4 SNPs on chrom
enrolled in nonrisk alleles carriers group includes the rest. (*P = 0.011 and PThe most direct way to address the genetic effects of
SNPs is to evaluate their effects on the transcription of
nearby genes or genes within 1 Mb 5’ or 3’ direction.
From our dataset, we did not find any correlation
between the SNPs on chromosome 17 and STAT3 or
STAT5A expression levels. However, both the publicly
available data analysis and experimental results indi-
cated a correlation between the SNPs on chromosome 17sion. (A) STAT5B mRNA expression grouped by risk alleles carriers and
f the 5 SNPs on chromosome 17 are enrolled in risk alleles carriers
mRNA expression grouped by risk alleles carriers and nonrisk alleles
osome 22 are enrolled in risk alleles carriers grope. The rest are
= 0.080 for Figure 2B).
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cations of transcription factor STAT5A/B and STAT3 have
been well established in prostate cancer. It has been
shown that they are constitutively active in both locally
confined and advanced prostate cancer and critical for the
growth of PC cells [21-26]. Furthermore, STAT5A/B and
STAT3 have potential importance in the promotion of
metastasis of PC cells [27-29]. Interestingly, it seems that
STAT5B particularly played a major role in cancer cell
viability and growth [29]. In spite of our small cohort, we
showed that the chromosome 17 prostate cancer risk
alleles are connected with higher expression of STAT5B.
This locus may represent a very promising molecular
marker for prostate cancer diagnostics and prognostics in
different ethnic populations.
The 5 SNPs on 9p24 are mapped to upstream of the
SMARCA2 gene. The encoded protein of this gene is
part of the large ATP-dependent chromatin remodeling
complex SNF/SWI, which is required for transcriptional
activation of genes normally repressed by chromatin.
SMARCA2 and/or its binding protein SMARCA4 is
absent or disrupted in approximately 17% of all human
adenocarcinomas [30]. Down-regulation of SMARCA2
expression was found in prostate cancer tissues and
conferred the proliferation advantage to prostate cancer
cells [31]. 9p24 was linked to ovarian cancer and colorectal
cancer [32,33]. To our knowledge this is the first time that
9p24 region has been associated to the risk of prostate
cancer.
On chromosome 22, rs5750627 and rs6001173 are
located in the intron region of the FAM227A gene that
encodes a hypothetical protein LOC646851. A region of
deletion on chromosome 22q13 is common to human
breast and colorectal cancers [34], suggesting the existence
of putative tumor suppressor gene(s) at this location.
Two 22q13 regions with marker D22S445 and D22S274,
respectively, are shown to be associated with aggressive
form of prostate cancer [35,36], and these two regions
are far from the region we have identified. rs138702 and
rs138712 are located in the intron region of the SUN2
gene. SUN2 encodes an inner nuclear membrane protein
that plays a major role in nuclear-cytoplasmic connection.
In mouse, loss of SUN2 increases the sensitivity to DNA
damage [37]. There is no evidence showing that SUN2 is
related to onset and development of cancer. In the present
study, we showed that prostate samples carrying homozy-
gous risk alleles of rs5750627, rs6001173 and rs138702
have a trend of higher expression of APOBEC3H. This
protein belongs to the apolipoprotein B mRNA-editing
enzyme catalytic polypeptide 3 families and encodes a
cytidine deaminase, which leads to G to A RNA editing.
Although APOBEC3 family is implicated in resistance to
gamma-retrovirus XMRV to reduce prostate cancer [38],
there is evidence that APOBEC3 family inhibit miRNAactivity to promote cancer metastasis [39], which repre-
sents a more general mechanism involved in cancer. A
meta-analysis of four GWAS identified a novel PCa
susceptibility locus, rs11704416, which also locates on
22q13 [40]. However, rs11704416 is not associated with
PCa risk in our cohort. This meta-analysis illustrated
the value of combining GWAS, which prompts us to
collect more PCa GWAS data of Arabs to identify further
susceptibility alleles in future study.
Arabs refer to people originally living in Western Asia
and North Africa. They share similar genealogical, linguistic
or cultural grounds. Recently, several studies reflected
the genetic makeup of Arab population and revealed the
diversity among the ethnic groups [41-43]. Although
analyses based on classical genetic markers did not show
discernable difference between different Berber- (North
African origin) and Arabic- (Western Asia origin) speaking
populations [41], mitochondrial and genome-wide SNP
genotyping data clearly indicate a back-to-Africa (east-to-
west) gene flow attribute [42]. SNPs usually occur in
ethnic-specific patterns. Only a small number of the risky
variants identified in other populations like Caucasian
[11], African American [12], Japanese [44] and Han [45]
can be replicated in the Tunisian population. According
to the migration study of North Africans [42], Tunisians
have the highest proportion of Maghrebi ancestry, with
or without little evidence of admixture of West Asian
population. The genetic structure differences between
Tunisians and West Asians may explain the difficulty
replicating the findings of the Tunisian GWAS prostate
cancer study with the population of Arab ancestry living in
Saudi Arabia and Qatar. Our observation highlighted the
ethnic heterogeneity of genetic mechanisms of prostate
cancer.
The present study based on a small-scale GWAS of
prostate cancer in Tunisians led to the identification of
3 clusters of SNPs in strong linkage disequilibrium with
high odd-ratios (OR > 2). When they are well designed
small-scale GWAS can lead to significant findings. For
instance, the search of genes underlying the age-related
macular degeneration undertaken with a small-scale
GWAS using DNA samples from only 96 cases and 50
control subjects led to a prominent finding showing that
a variant in complement factor H gene has an important
causative effect (OR = 7.4) [46]. A case–control study of
American African men on the association of EphB2
SNPs with PCa risk suggests that the power of GWAS
study relies on high resolution haplotype maps based on
African population [47]. Further analysis of our GWAS
study should be performed when a high-resolution genetic
maps of Arabs is available.
Although this study, showing the strong association of
SNPs located on chromosome 9, 17 and 22 with prostate
cancer in Tunisians, suggests that genes in chromosomal
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cancer, further studies are needed to clarify their role in
the pathogenesis of the disease. Our data also suggest a
need for large-scale prostate cancer associated SNPs
typing in Tunisians with prostate cancer. Replication of
our findings in other Arab North African populations will
be of use in determining whether the relations between
these risk factors and the development of prostate cancer
can be generalized.
Additional files
Additional file 1: Figure S1. Multidimensional scaling (MDS) analysis of
sample variation pattern in 202 arrays of good quality. A total of 221
arrays have been hybridized, in which 202 passed the quality control
criteria. (A) Two outliers were identified by PC1, three outliers by PC2,
and (B) two outliers by PC4. Figure S2. Manhattan plot of the strength of
association (−log10 (P) values; Y-axis) between SNPs (X-axis by
chromosome and chromosomal position) and prostate cancer risk. SNPs
on each individual chromosome are shown with the same color in an
order from chromosome 1 to 22 (left→ right). Figure S3. eQTL analysis.
(A) The correlation between SNPs on chromosome 17 and mRNA
expression of STAT5B in lymphoblastoid cells from 75 Geneva individuals.
The mRNA was quantified by array probe ILMN_1777783. (B) The
correlation between SNPs on chromosome 22 and mRNA expression of
STAT5B in lymphoblastoid cells from 75 Geneva individuals. The mRNA
was quantified by array probe ILMN_1664828. The data of rs6001173 and
rs138172 are not available from the online data. (C) The correlation
between SNPs on chromosome 22 and mRNA expression of SUN2 in 166
adipose (A), 156 lymphoblastold cell line (L) and 160 skin (S) samples,
respectively, from healthy female twins (Twins 1 and 2). The mRNA was
quantified by array probe ILMN_2099301.
Additional file 2: Table S1. Primer sequences used in real-time
quantitative PCR.
Additional file 3: Table S2. The association of top 5749 SNPs identified
by GWAS.
Additional file 4: Table S3. GWAS PCa genotype distributions in
patients and controls.
Additional file 5: Table S4. The results of permutation test of fourteen
PCa SNPs.
Additional file 6: Table S5. The replication study in the population
with Arab ancestry living in Qatar and Saudi Arabia (155 cases and 182
controls).
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